A tracer targeting CD8+ T cell immune response to oncolytic herpes simplex virus (oHSV) M002 immunotherapy was evaluated as a proof of concept in a syngeneic glioblastoma model [113]. The gene discussed is CD8A; the disease is glioblastoma.